Moreover, EGCG ameliorates the liver tissue affected by non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) using, for example, the ob/ob mice model, which is a mutant mouse that eats excessively due to mutations in the LEP (Leptin) gene (Fiorini et al., 2005; Chung et al., 2012). This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.